Literature DB >> 2189875

Relapse and recurrence in unipolar major depression: short-term and long-term approaches.

M E Thase1.   

Abstract

Relapse and recurrence following successful short-term treatment of major depression are common and vexing clinical problems. The risk of relapse and recurrence is reviewed, as is evidence pertaining to pharmacologic and psychosocial strategies for continuation and maintenance therapy. Up to 6 months' continuation treatment following short-term treatment response is recommended routinely for virtually all patients. Based on available evidence, a more prolonged course of maintenance pharmacotherapy is strongly recommended for patients with residual symptomatology and/or a past history of chronicity or multiple depressive episodes. Further research is necessary to identify the specific indications for combining psychotherapy and pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189875

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  The added costs of depression to medical care.

Authors:  K Franco; M Tamburino; N Campbell; J Zrull; C Evans; D Bronson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 2.  Vagus nerve stimulation (VNS) for depression: what do we know now and what should be done next?

Authors:  Ziad Nahas; Carol Burns; Milton J Foust; Baron Short; Tal Herbsman; Mark S George
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

Review 3.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

4.  Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin.

Authors:  E J Hatziandreu; R E Brown; D A Revicki; R Turner; J Martindale; S Levine; J E Siegel
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 5.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

6.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 7.  Sertraline versus other antidepressive agents for depression.

Authors:  Andrea Cipriani; Teresa La Ferla; Toshi A Furukawa; Alessandra Signoretti; Atsuo Nakagawa; Rachel Churchill; Hugh McGuire; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 8.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 9.  What to do if an initial antidepressant fails?

Authors:  Roger S McIntyre; Aleksandra Müller; Deborah A Mancini; Eric S Silver
Journal:  Can Fam Physician       Date:  2003-04       Impact factor: 3.275

10.  The cumulative impact of nonsevere life events predicts depression recurrence during maintenance treatment with interpersonal psychotherapy.

Authors:  Shannon N Lenze; Jill M Cyranowski; Wesley K Thompson; Barbara Anderson; Ellen Frank
Journal:  J Consult Clin Psychol       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.